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Pickles: Dudes, we party too hard, so our bodies are in terrible shape. 
We gotta trick the doctor by making it seem like we're in really good 
shape. And there's only one way to do that. Bleach... Here, drink this 
Murderface... 
 
Skwisgaar: Uhh, maybe this ams a stupid question, buts, why don'ts we 
just pours bleach into our cups of...urines? 
 
Pickles: No! Drink the bleach! 
 
Nathan: Bleach is healthy. It's mostly water. And we are mostly water. 
Therefore, we are bleach. 
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 Abstract 
 
In Australia and throughout the world, cannabis is one of the most widely used recreational 
substances. Whilst the recreational use of cannabis remains widely controversial, and the 
detection of its use in a range of biological matrices is of vital importance for drug testing 
laboratories and law enforcement agencies. The detection of drugs of abuse is critical in 
various areas, including pre-employment and post-incident drug screening, and sports drug 
testing.  
The use of cannabis by an individual may be ascertained by identifying the main metabolites of 
the major psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol (THC), in biological 
matrices such as urine. The principal metabolite of THC is 11-nor-Δ9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH), and may be detected in urine in both its free and glucuronide-
bound form, with detection of either regarded as compelling evidence for the use of cannabis 
by an individual. 
Detection of THC-COOH by a range of instrumental techniques in drug testing laboratories is 
well established. However, this metabolite is known to be susceptible to reaction with certain 
adulterants. Adulteration of urine samples with oxidising adulterants has been shown to 
effectively mask cannabis use through reaction with THC-COOH. As such, the primary goals of 
this research are to assess the efficacy of a range of adulterants on the detection of THC-COOH 
in vitro, ascertain whether novel reaction products specific to the reaction of THC-COOH with 
selected adulterants form, and to assess the potential of these compounds to act as markers of 
both cannabis use and urine adulteration.  
Successful detection of a range of reaction products of THC-COOH was achieved, and three 
adulterants selected for further research: pyridinium chlorochromate, Betadine and bleach. 
Structural elucidation of these reaction products was attempted, and validated methods were 
developed for the quantitative detection of THC-COOH and qualitative detection of the targed 
reaction products following urine adulteration. Kinetics, pH and stability studies demonstrated 
that these reaction products formed under a range of pH and sample storage conditions, and 
critically, remained detectable for at least twenty days following adulteration.  
 Detection of these potential markers of urine adulteration was also successfully achieved 
through the adulteration of authentic cannabis-positive urine specimens. This detection in 
authentic urine specimens is considered significant, as it highlights the potential for these 
novel compounds to be incorporated into current drug testing regimes employed by drug 
testing laboratories, and a potential means by which both cannabis use and urine adulteration 
may be conclusively identified. 
 
  
 
